Tumor immune biomarkers
PD, tumor
DISEASE, TUMOR
PD-L1 (22C3) testing showed 4 patients who were PD-L1 positive, 4 patients who were PD-L1 negative, and 2 patients who did not have PD-L1 results. Stromal TILs analysis of available tumor tissue was performed for 4 patients and showed 1 CR patient with 90% TILs (lymph node), 1 UPR patient with 5% TILs (axillary mass), 1 UPR patient with 10% TILs (liver), and 1 PD patient with 3% TILs (axillary mass). Five patients did not have TILs analysis due to exhausted tissue block. Overall, no association between baseline levels of TILs or PD-L1 status with response was observed (Supplemental Table 2). We do note that the patient with CR had 90% TILs in the biopsied lymph node, although we were unable to assess TILs in the patient’s other disease sites such as lung and dermal tissues. It is therefore unclear if the high TIL density is associated with the biopsy site of lymph node or with patient response. Genomic alterations for patients with sequencing results did not show association with response (Supplemental Table 3).